EX-10.2
from 8-K
21 pages
This Registration Rights Agreement (This “Agreement”), Dated as of August 12, 2025, Is Entered Into by and Among X4 Pharmaceuticals, Inc., a Delaware Corporation (The “Company”), and the Several Investors Signatory Hereto (Individually as an “Investor” and Collectively Together With Their Respective Permitted Assigns, the “Investors”). Capitalized Terms Used Herein and Not Otherwise Defined Herein Shall Have the Respective Meanings Set Forth in the Securities Purchase Agreement by and Among the Parties Hereto, Dated as of the Date Hereof (As Amended, Restated, Supplemented or Otherwise Modified From Time to Time, the “Purchase Agreement”)
12/34/56
EX-10.37
from 10-K
2 pages
Amendment No. 3 to the Master Services Agreement This Amendment No. 3 (“Amendment 3”) to the Agreement (As Defined Below) Is Made as of August 3, 2023 (“Amendment 3 Effective Date”), by and Between Catalent Greenville, Inc., a North Carolina Corporation, Having a Principal Place of Business at 1240 Sugg Parkway, Greenville, Nc 27834 (“Catalent”), and X4 Pharmaceuticals Inc., a Delaware Corporation With a Business Address at 61 North Beacon Street, 4th Floor, Boston, Ma 02134 (“Company”)
12/34/56
